Citadel Advisors’s Applied Therapeutics APLT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-474,094
| Closed | -$223K | – | 12702 |
|
|
2025
Q2 | $147K | Buy |
+474,094
| New | +$183K | ﹤0.01% | 10972 |
|
|
2025
Q1 | – | Sell |
-727,626
| Closed | -$428K | – | 14418 |
|
|
2024
Q4 | $623K | Buy |
727,626
+374,143
| +106% | +$2.35M | ﹤0.01% | 8064 |
|
|
2024
Q3 | $3M | Buy |
353,483
+277,030
| +362% | +$1.63M | ﹤0.01% | 4780 |
|
|
2024
Q2 | $357K | Buy |
76,453
+73,344
| +2,359% | +$347K | ﹤0.01% | 8777 |
|
|
2024
Q1 | $21.1K | Sell |
3,109
-74,503
| -96% | -$334K | ﹤0.01% | 12977 |
|
|
2023
Q4 | $260K | Buy |
77,612
+77,239
| +20,708% | +$192K | ﹤0.01% | 9444 |
|
|
2023
Q3 | $929 | Sell |
373
-8,158
| -96% | -$13.4K | ﹤0.01% | 13953 |
|
|
2023
Q2 | $10.9K | Buy |
+8,531
| New | +$11.3K | ﹤0.01% | 13168 |
|
|
2023
Q1 | – | Sell |
-374
| Closed | -$284 | – | 14664 |
|
|
2022
Q4 | $284 | Buy |
+374
| New | +$296 | ﹤0.01% | 14702 |
|
|
2022
Q3 | – | Sell |
-78,843
| Closed | -$94.6K | – | 12540 |
|
|
2022
Q2 | $75K | Buy |
78,843
+62,158
| +373% | +$102K | ﹤0.01% | 11642 |
|
|
2022
Q1 | $35K | Buy |
16,685
+6,027
| +57% | +$16.1K | ﹤0.01% | 13014 |
|
|
2021
Q4 | $95K | Buy |
+10,658
| New | +$140K | ﹤0.01% | 12766 |
|
|
2021
Q3 | – | Sell |
-13,119
| Closed | -$227K | – | 13754 |
|
|
2021
Q2 | $273K | Buy |
+13,119
| New | +$248K | ﹤0.01% | 11489 |
|
|
2020
Q3 | – | Sell |
-63,322
| Closed | -$2.29M | – | 10031 |
|
|
2020
Q2 | $2.29M | Buy |
63,322
+22,630
| +56% | +$947K | ﹤0.01% | 4331 |
|
|
2020
Q1 | $1.33M | Buy |
+40,692
| New | +$1.65M | ﹤0.01% | 4822 |
|
Citadel Advisors's APLT Position: Q3 2025 in Review
Citadel Advisors sold out of Applied Therapeutics (APLT) in Q3 2025, closing a stake of 474,094 shares — an estimated $223K sold.
Citadel Advisors first reported a position in APLT in Q1 2020 and held it in 15 quarters. The position peaked at $3M in Q3 2024. 70 funds tracked by Wall St. Rank hold APLT as of Q3 2025.
- Citadel Advisors reported no remaining Applied Therapeutics position as of Q3 2025 after selling out during the quarter.
- Citadel Advisors sold 474,094 Applied Therapeutics shares in Q3 2025, an estimated $223K.
- Citadel Advisors first reported a position in Applied Therapeutics in Q1 2020 and held it in 15 quarters.
- Citadel Advisors's Applied Therapeutics position peaked at $3M in Q3 2024.
- 70 funds tracked by Wall St. Rank held Applied Therapeutics as of Q3 2025.
Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.